Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Cellulite Cream

Study Looks At HIV, Risk Behaviors Among Male Clients Of Sex Workers In Tijuana, Mexico
"A large percentage" of U.S. and Mexican men who regularly engage in sexual activity with sex workers in Tijuana, Mexico, do not use condoms and have a history of substance and alcohol use, according to a study published in the online journal AIDS, the Los Angeles Times" blog "L.A. Now" reports. The study, by researchers from Mexico and the University of California-San Diego, surveyed 400 men - both Mexico and U.S. residents - and found that half of the men had unprotected sex with a female sex worker within the last four months. Researchers noted that although Tijuana authorities require that sex workers be registered and tested regularly for HIV, "only about half of [sex workers] have registered or been tested," according to the blog. Thomas Patterson of the UC-San Diego"s department of psychiatry and the Veterans Affairs health center, said the findings indicate a need for an educational campaign targeting men who frequent sex workers (Perry, 7/11).
generic viagra online
Quality And Purity Of Popular Stevia Sweetener Strengthened By New Reference Standards
As the number of food and beverage products sweetened with stevia-based ingredients continues to grow in the United States and worldwide, the U.S. Pharmacopeial (USP) Convention announces that new reference standards for Rebaudioside A and Stevioside are now available. The reference standards for these two ingredients complement the soon to be released written testing standard for high-purity Rebaudioside A in the Food Chemicals Codex (FCC), a collection of documentary standards for food ingredients that allow manufacturers to demonstrate the quality, and thus related aspects of safety, of the products they provide to consumers.
News of the day
Severe COPD May Lead To Cognitive Impairment
Severe chronic obstructive pulmonary disease (COPD) is associated with lower cognitive function in older adults, according to research from Mount Sinai School of Medicine. Researchers compared cognitive performance in over 4,150 adults with and without COPD and found that individuals with severe COPD had significantly lower cognitive function than those without, even after controlling for confounding factors such as comorbidities.
Medical Devices

Positive CHMP Opinion For JAVLOR(R) In Metastatic Treatment Of Bladder Cancer After Failure Of A Prior Platinum-Containing Regimen

Laboratoires Pierre Fabre announce that the Committee for Medicinal Products for Human Use (CHMP), the scientific advisory committee of the European Medicines Agency (EMEA), has issued a positive opinion supporting approval and is recommending to grant marketing authorisation for JAVLOR(R) as monotherapy in metastatic treatment of bladder cancer (advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen). CHMP has issued a positive opinion based on two phase II study results and on the only phase III randomized study ever conducted in the indication of metastatic treatment of bladder cancer after failure of a prior platinum-containing regimen. When the EMEA will grant the marketing authorization, JAVLOR(R) will become the first monotherapy approved in Europe for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen, where the expectation is important for both oncologists and patients. In Europe the burden of bladder cancer is significative with an estimated 100.000 new cases and 50.000 deaths annually; most of cases are related to the use of tobacco products. Jean-Pierre Garnier, Chief Executive Officer of Pierre Fabre SA, stated: "The favourable opinion of the CHMP for JAVLOR(R) confirms the therapeutic interest of our anticancer product, strengthened by the clinical data of our file. Again, it rewards the quality of work done by our colleagues dedicated to R&D. JAVLOR(R) will introduce innovative therapy to physicians and patients in an area considered as an unmet medical need". This approval is a significant milestone for Laboratoires Pierre Fabre as JAVLOR(R) represents one of the leading products of their pipeline and these positive results reward their important efforts in oncology research. About JAVLOR(R) (vinflunine): Discovered by scientists at the Pierre Fabre Research Center, vinflunine is a new bi-fluorinated MTI (Microtubule inhibitor) obtained by chemistry exploiting the reactivity of Vinca scaffold in superacidic media. Such strategy, finalized in collaboration with experts at the University of Poitiers (France), enabled the selective introduction of two fluorine atoms in a part of that structure previously inaccessible by classic chemistry, thereby leading to the first bi-fluorinated vinca alkaloid. Besides its original structure, JAVLOR(R) exhibits unique pharmacological properties and is also devoid of any unpredictable major toxicity and does not induce cumulative toxicity. Its every 3 weeks administration enables convenient hospital treatment on an out patient basis (a 20 minutes infusion without any IV premedication). JAVLOR(R) 25 mg/ml solution for infusion has been approved as monotherapy for the treatment of adult patients with advanced or metastatic transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen. About Laboratoires Pierre Fabre Pierre Fabre group, France"s second biggest independent pharmaceutical laboratory, achieved a turnover of 1.75 billion euros in 2008. Approximatively 10,000 people including 1,400 in the research sector, are employed. Its therapeutical areas are ethical products, healthcare products and dermocosmetics with the brands Avene, Ducray, A Derma, Galenic, Klorane and Rene Furterer. In 2008, Pierre Fabre Medicament dedicated 33% of its annual turnover to R&D in five main therapeutic directions: oncology, the Central Nervous System, cardiology, internal medicine /urology and dermatology. Pierre Fabre SA


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009